Parkinson's disease (PD) is the second most common neurodegenerative disease
worldwide, and its treatment remains a big challenge. The pathogenesis of PD may be …

Objective: The objective of this review was to update evidence‐based medicine
recommendations for treating motor symptoms of Parkinson's disease (PD). Background …

Background Subcutaneous apomorphine infusion is a clinically established therapy for
patients with Parkinson's disease with motor fluctuations not optimally controlled by oral …

Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

Advanced Parkinson's disease is characterized by the presence of motor fluctuations,
various degree of dyskinesia, and disability with functional impact on activities of daily living …

Importance CatecholO-methyltransferase (COMT) inhibitors are an established treatment for
end-of-dose motor fluctuations associated with levodopa therapy in patients with Parkinson …

Levodopa is the most effective medication for the treatment of the motor symptoms of
Parkinson's disease. However, over time, the clinical response to levodopa becomes …

Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects
elderly people and constitutes a major source of disability worldwide. Notably, the …

Parkinson's Disease (PD) is a disease that involves neurodegeneration and is characterised
by the motor symptoms which include muscle rigidity, tremor, and bradykinesia. Other non …

This article summarizes (1) the recent achievements to further improve symptomatic therapy
of motor Parkinson's disease (PD) symptoms,(2) the still-few attempts to systematically …